JENNIFER NIEMI: Open Payments
NPI 1598054249 · LYNNWOOD, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,379 in 75 payments from 17 companies in 2025. Trend: 2023 $1,716 · 2024 $1,329 · 2025 $1,379
Food & beverage: $1,379
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $331 |
| GlaxoSmithKline, LLC. | 26 | $241 |
| GENZYME CORPORATION | 11 | $196 |
| Insmed, Inc. | 4 | $123 |
| United Therapeutics Corporation | 2 | $118 |
| Verona Pharma, Inc. | 4 | $89 |
| Vifor Pharma, Inc. | 3 | $45 |
| Grifols USA, LLC | 2 | $40 |
| Baxter Healthcare | 2 | $34 |
| Electromed, Inc. | 2 | $31 |
Products named: DUPIXENT, TRELEGY ELLIPTA, AIRSUPRA, Arikayce, NUCALA, FASENRA, TEZSPIRE, Ohtuvayre.
Industry payments across WA — which companies pay providers there.
